Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $200.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target boosted by equities research analysts at JPMorgan Chase & Co. from $168.00 to $200.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 20.45% from the company’s current price.

Several other equities research analysts also recently issued reports on the stock. Cantor Fitzgerald increased their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 25th. UBS Group assumed coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price target on the stock. Morgan Stanley set a $180.00 price target on Ascendis Pharma A/S in a research note on Tuesday, February 18th. Evercore ISI upped their price objective on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 18th. Finally, The Goldman Sachs Group raised their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and a consensus target price of $204.64.

Ascendis Pharma A/S Stock Up 0.9 %

ASND stock opened at $166.05 on Tuesday. The business’s fifty day moving average is $140.06 and its 200-day moving average is $135.30. The company has a market cap of $10.08 billion, a P/E ratio of -23.39 and a beta of 0.62. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.64. Research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several large investors have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. grew its stake in Ascendis Pharma A/S by 54.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company’s stock valued at $375,226,000 after buying an additional 960,504 shares during the last quarter. Capital International Investors boosted its holdings in shares of Ascendis Pharma A/S by 35.7% during the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company’s stock worth $394,183,000 after acquiring an additional 753,859 shares during the period. Groupama Asset Managment bought a new stake in shares of Ascendis Pharma A/S during the third quarter worth approximately $60,000. RA Capital Management L.P. grew its position in shares of Ascendis Pharma A/S by 4.1% in the fourth quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company’s stock valued at $1,392,221,000 after purchasing an additional 402,316 shares during the last quarter. Finally, Vestal Point Capital LP increased its stake in shares of Ascendis Pharma A/S by 108.0% during the fourth quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company’s stock worth $71,588,000 after purchasing an additional 270,000 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.